Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer

Acta Oncologica

Volumn 50, Issue 4, 2011, Pages 574-577

  Larsen, Finn Ole ^a   Pfeiffer, Per ^b   Nielsen, Dorte ^a   Skougaard, Kristin ^a   Qvortrup, Camilla ^b   Vistisen, Kirsten ^a   Fromm, Anne Lene ^a   Jørgensen, Trine L ^b   Bjerregaard, Jon K ^b   Hoegdall, Estrid ^a   Jensen, Benny V ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN;

ADULT; AGED; ANAPHYLAXIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CLINICAL ARTICLE; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; GENE MUTATION; HUMAN; HYPERTENSION; MALE; METASTASIS; NAIL DISEASE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN TOXICITY; THROMBOCYTOPENIA; THROMBOEMBOLISM; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79955632360     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2010.546369     Document Type: Article

References (14)

1. Brentjen R, Saltz L. Epidermal growth factor receptor blockade and treatment of solid tumor malignancies. DeVita JVT, Helmann S, Rosenberg SA, editors. In: Progress in oncology. Boston, MA: Jones and Bartlett; 2002. pp 113-28.
2. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45. (Pubitemid 38944402)
3. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au H, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-8. (Pubitemid 350106711)
4. Pfeiffer P, Nielsen D, Yilmaz M, Iversen A, VejløC, Jensen BV. Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Acta Oncol 2007;46:697-701. (Pubitemid 46911904)
5. Pfeiffer P, Nielsen D, Bjerregaard J, Qvortrup C, Yilmaz M, Jensen B. Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann Oncol 2008;19:1141-5. (Pubitemid 351796340)
6. Tabernero J, Pfeiffer P, Cervantes A. Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: An effective, more convenient alternative to weekly administration? Oncologist 2008;13:113-9. (Pubitemid 351342574)
7. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-64. (Pubitemid 46797944)
8. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 2004;25:581-611. (Pubitemid 39099316)
9. Saltz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM, et al. Randomized Phase II Trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 Study. J Clin Oncol 2007;25:4557-61. (Pubitemid 350035312)
10. Halama N, Herrmann C, Jaeger D, Hermann T. Treatment with cetuximab, bevacizumab and irinotecan in heavily pretreated patients with metastasized colorectal cancer. Anticancer Res 2008;28:4111-6.
11. Tol J, Koopman CJ, Cats A, Cats A, Creemers GJ, Schrama JG, et al. A randomized phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol 2008;19:734-8. (Pubitemid 351461045)
12. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab and panitumumab compared with chemotherapy and bevacizumab alone for metastasis colorectal cancer. J Clin Oncol 2009;5:672-80.
13. Amado RG, Wolf M, Peeters M, Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab effi-cacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
14. Karapetis CS, Khambata-Ford S, Jonker D, O'Callagan CJ, Tu D, Tebbutt NC, et al. K-RAS mutations and benefit from Cetuximab in advanced colorectal cancer. New Engl J Med 2008;359:1757-65.